Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Closing this gap isn’t just good business, it’s a powerful economic lever. When people have appropriate and comprehensive ...

Abortion providers are in federal court in Charlottesville seeking to make the abortion pill mifepristone more accessible by ...

It’s really important that we protect ... safe access to medication abortion no matter where people live — Virginia is ...

The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS). Also Read: Bristol Myers ...

This drug is available only under a Risk Evaluation and Mitigation Strategy (REMS). For drugs that come with serious safety risks, a REMS informs prescribers and patients about the risks and sets ...

The whole issue revolves around REMS, the shorthand for the FDA's Risk Evaluation and Mitigation Strategy programs. REMS are typically demanded by the FDA for potentially risky drugs and are a ...

Approved last year for patients with hypertension currently not controlled on other blood pressure-lowering agents, the drug previously was only available in the US through the FDA’s risk evaluation ...

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 Phase III data showed ...